GABA Transporter 1
Overview
Mermaid diagram (expand to render)
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GABA Transporter 1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>GAT1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>GABA Transporter 1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=GAT1" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">18 edges</a></td>
</tr>
</table>
GABA is a human gene. Variants in GABA have been implicated in Epilepsy, Alzheimer's Disease, Parkinson's Disease. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
GABA transporter 1 (GAT1) is a sodium-dependent GABA transporter that reuptakes GABA from the synaptic cleft back into presynaptic [neurons](/entities/neurons) and surrounding glial cells["@borden1994"]. It belongs to the SLC6A family of neurotransmitter transporters["@gasnier2004"] and is the major mechanism for terminating GABAergic signaling.
Gene Overview
The SLC6A1 gene encodes GAT1, a membrane protein consisting of 599 amino acids with 12 transmembrane domains[@richerson2003]. GAT1 utilizes the sodium gradient (and optionally chloride) to transport GABA against its concentration gradient, effectively clearing GABA from the extracellular space within milliseconds of synaptic release.
Structure and Mechanism
GAT1 exhibits several key structural features[@kanner2003]:
- 12 transmembrane helices forming the translocation pore
- Intracellular N-terminus and C-terminus regulating trafficking and function
- Sodium binding sites (2-3 Na+ ions per GABA transport cycle)
- Cl- dependence for optimal transport activity
The transport cycle involves conformational changes that alternately expose the GABA binding site to the extracellular and intracellular environments. This electrometric transport can generate currents detectable by patch-clamp electrophysiology.
Expression Pattern
In the brain, GAT1 is expressed primarily on[@conti1999][@decavel2000]:
- Presynaptic neurons: Particularly GABAergic interneurons
- [Astrocytes](/entities/astrocytes): Throughout gray matter regions
- Axon terminals: Especially in cortical and hippocampal circuits
High expression is observed in the cerebral [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus) (CA1-CA3 regions and dentate gyrus), cerebellum (Purkinje cell layer), basal ganglia (striatum and globus pallidus), and brainstem nuclei[@conti1999].
Physiological Role
GAT1 serves several critical functions in neural signaling:
Synaptic termination: Rapidly clears GABA from the synaptic cleft, limiting the duration of GABAergic inhibition
Extracellular GABA regulation: Maintains low baseline extracellular GABA concentrations
GABA recycling: Facilitates GABA reuse through the glutamate-GABA cycle
Cl- homeostasis: Contributes to neuronal chloride regulationDisease Associations
Epilepsy
GAT1 deficiency leads to impaired GABA reuptake, resulting in hyperexcitability and seizures[@jensen2002].
GAT1 knockout mice exhibit spontaneous seizures and increased excitability[@jensen2002]. GAT1 inhibitors (tiagabine) are used as anticonvulsants[@madsen2009] but can paradoxically cause seizures at high doses.
Alzheimer's Disease
Altered GABAergic signaling contributes to cognitive deficits in AD[@melone2014][@cherubini2001]. GAT1 expression is modified in AD brain tissue, and GAT1 modulators are being explored as therapeutic agents to restore inhibitory-excitatory balance[@melone2014].
Parkinson's Disease
GAT1 modulators may have therapeutic potential for L-DOPA-induced dyskinesias[@norris2019]. The basal ganglia GABAergic system is dysregulated in PD, and GAT1 represents a potential therapeutic target[@norris2019].
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Borden et al., GABA transporter heterogeneity (1994) (1994)](https://pubmed.ncbi.nlm.nih.gov/7964357/)
[Unknown, Richerson & Wu, Sodium-coupled GABA transport (2003) (2003)](https://doi.org/10.1002/neu.10184)
[Conti et al., GAT1 expression in human brain (1999) (1999)](https://pubmed.ncbi.nlm.nih.gov/10489921/)
[Schousboe et al., GABA transporters as drug targets (2003) (2003)](https://doi.org/10.1016/S0149-7634(03)
[Jensen et al., GAT1 knockout mice and epilepsy (2002) (2002)](https://doi.org/10.1093/epo/rev003)
[Madsen et al., Tiagabine clinical efficacy (2009) (2009)](https://doi.org/10.1002/epi.12471)
[Melone et al., GAT1 in Alzheimer's disease (2014) (2014)](https://doi.org/10.1016/j.neurobiolaging.2014.02.012)
[Unknown, Norris & Schaller, GAT1 modulation in Parkinson's disease (2019) (2019)](https://doi.org/10.3233/JPD-191619)
[Unknown, Kanner & Schuldiner, GABA transporter structure (2003) (2003)](https://doi.org/10.1016/S0092-8674(03)
[Unknown, Gasnier, SLC6A neurotransmitter transporter family (2004) (2004)](https://doi.org/10.1016/j.tips.2004.08.002)
[Unknown, Decavel & Van den Pol, GAT1 in astrocytes (2000) (2000)](https://pubmed.ncbi.nlm.nih.gov/10805794/)
[Unknown, Cherubini & Conti, GABAergic signaling alterations in AD (2001) (2001)](https://pubmed.ncbi.nlm.nih.gov/11418858/)Pathway Diagram
The following diagram shows the key molecular relationships involving GABA Transporter 1 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)